Stage IIIA-N2 non-small cell lung cancer (NSCLC): comparison of prognostic factors in 257 patients treated with surgery (S) versus induction chemotherapy plus surgery (IC+S) Source: Eur Respir J 2002; 20: Suppl. 38, 597s Year: 2002
Long-term follow-up comparing postoperative chemotherapy or radiotherapy and surgery with surgery alone in resectable nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 131s Year: 2001
Survival and recurrences following surgical treatment of N2 NSCLC Source: Eur Respir J 2006; 28: Suppl. 50, 718s Year: 2006
Treatment of potentially resectable locoregional (stage III) non-small cell lung cancer Source: Annual Congress 2005 - PG2 - Lung cancer: non-small cell lung cancer treatment Year: 2005
Stage IIIA/B NSCLC: long-term results of induction chemotherapy and surgery Source: ISSN=ISSN 1810-6838, ISBN=, page=279 Year: 2008
Indcution chemotherapy and radiotherapy vs. induction and simultaneous radiochemotherapy in inoperable stage III NSCLC. Update on BROCAT study CTRT 99/97 Source: Eur Respir J 2006; 28: Suppl. 50, 833s Year: 2006
Factors predicting complete surgical resection after induction chemotherapy in patients with initially unresectable non-small cell lung cancer (NSCLC) treated in a randomised trial Source: Eur Respir J 2003; 22: Suppl. 45, 162s Year: 2003
Induction chemotherapy and simultaneous radiochemotherapy or radiotherapy in inoperable NSCLC (stage IIIA/IIIB) Source: Eur Respir J 2002; 20: Suppl. 38, 399s Year: 2002
Efficacy of induction chemotherapy and following simultaneous radiochemotherapy versus induction chemotherapy and radiotherapy alone in inoperable NSCLC (Stage IIIA/IIIB): update of CT/RT 99/97 Source: Annual Congress 2004 - Management of lung cancer and innovative therapies Year: 2004
Pre-operative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage nonsmall cell lung cancer Source: Breathe 2010; 7: 196-197 Year: 2010
Is there any survival benefit of surgery after neoadjuvant chemoradiotherapy and persisting pn2/3 in stage III NSCLC? Source: Annual Congress 2009 - Diagnosis and treatment of lung cancer Year: 2009
Adjuvant chemotherapy uptake and survival of patients with NSCLC after complete resection: Single institution/single area experience. Source: International Congress 2017 – Lung cancer: important scientific reports from endoscopists and thoracic surgeons Year: 2017
Pattern of response and recurrence after induction chemotherapy and [dsquote]involved field[dsquote] thoracic radiotherapy to 70 Gy in stage III NSCLC Source: Eur Respir J 2001; 18: Suppl. 33, 375s Year: 2001
Survival and postoperative complication after neoadjuvant therapy in resectable stage IIIA-N2 non-small cell lung cancer: a balancing exercise Source: Eur Respir J 2003; 22: Suppl. 45, 31s Year: 2003
Chemotherapy plus resection is not better than chemoradiotherapy for baseline unresectable stage IIIA-N2 NSCLC Source: ISSN=ISSN 1810-6838, ISBN=, page=380 Year: 2007
Improved survival associated with neoadjuvant chemoradiation and surgery vs other means of treatment for NSCLC N2 patients (clinical stage IIIa and IIIb) Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015
A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2003; 22: Suppl. 45, 162s Year: 2003
Impact of neoadjuvant therapies on surgical indications and early postoperative outcome Source: Annual Congress 2005 - Multidisciplinary treatment of non-metastatic non-small cell lung cancer: contemporary concepts Year: 2005
The efficacy of induction chemoradiotherapy followed by surgery in stage IIIA-proven N2 NSCLC and the influence of lymph node downstage on the incidence of postoperative recurrence Source: International Congress 2018 – Lung cancer: personalised medicine Year: 2018
Treatment of unresectable locoregional (stage III) non-small cell lung cancer Source: Annual Congress 2005 - PG2 - Lung cancer: non-small cell lung cancer treatment Year: 2005